BiotechTube

DS-1205c + Gefitinib

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non Small Cell Lung Cancer

Conditions

Non Small Cell Lung Cancer

Trial Timeline

Sep 21, 2018 → Jun 29, 2020

NCT ID
NCT03599518

About DS-1205c + Gefitinib

DS-1205c + Gefitinib is a phase 1 stage product being developed by Daiichi Sankyo for Non Small Cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03599518. Target conditions include Non Small Cell Lung Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Non Small Cell Lung Cancer were approved

Approved (20) Terminated (2) Active (0)
✅mouse nerve growth factorSun PharmaceuticalApproved
✅Pemetrexed + CarboplatinEli LillyApproved
✅pemetrexedEli LillyApproved
✅Osimertinib+cisplatin or carboplatin + pemetrexed EditAstraZenecaApproved
✅DurvalumabAstraZenecaApproved
✅Gefitinib + DocetaxelAstraZenecaApproved
✅OsimertinibAstraZenecaApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03599518Phase 1Terminated

Competing Products

20 competing products in Non Small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
mRNA-1769ModernaPhase 2
0
BBP-398 with nivolumabBridgeBio PharmaPhase 1
18
Pemetrexed + CarboplatinEli LillyPhase 3
40
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
SelpercatinibEli LillyPre-clinical
26
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
40
NBTXR3NanobiotixPhase 1/2
33
PemetrexedEli LillyPre-clinical
26
pemetrexed + erlotinibEli LillyPhase 2
35
LY3295668 ErbumineEli LillyPhase 1
29
FYB206 + FYB206 + KeytrudaFormycon AGPhase 3
22
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
37
pemetrexed + cisplatinEli LillyPhase 2
27
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
35
CetuximabEli LillyPhase 1
29
pemetrexed + docetaxelEli LillyPhase 3
40
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
35
PemCarbo + Pem onlyEli LillyPhase 3
36
TNG456 + abemaciclibEli LillyPhase 1/2
39